Archaeological Simulation and the Testing Paradigm

2016 ◽  
pp. 131-156 ◽  
Author(s):  
Thomas G. Whitley
Keyword(s):  
Testing Paradigm

A testing paradigm for quantifying ICC profilers

2019 ◽  
Vol 2019 (1) ◽  
pp. 80-85
Author(s):  
Pooshpanjan Roy Biswas ◽  
Alessandro Beltrami ◽  
Joan Saez Gomez
Keyword(s):  
Digital Camera ◽  
Visual Assessment ◽  
Just Noticeable Difference ◽  
Color Management ◽  
Color Gamut ◽  
Gamut Mapping ◽  
Digital File ◽  
Mapping Process ◽  
Testing Paradigm

To reproduce colors in one system which differs from another system in terms of the color gamut, it is necessary to use a color gamut mapping process. This color gamut mapping is a method to translate a specific color from a medium (screen, digital camera, scanner, digital file, etc) into another system having a difference in gamut volume. There are different rendering intent options defined by the International Color Consortium [5] to use the different reproduction goals of the user [19]. Any rendering intent used to reproduce colors, includes profile engine decisions to do it, i.e. looking for color accuracy, vivid colors or pleasing reproduction of images. Using the same decisions on different profile engines, the final visual output can look different (more than one Just Noticeable Difference[16]) depending on the profile engine used and the color algorithms that they implement. Profile performance substantially depends on the profiler engine used to create them. Different profilers provide the user with varying levels of liberty to design a profile for their color management needs and preference. The motivation of this study is to rank the performance of various market leading profiler engines on the basis of different metrics designed specifically to report the performance of particular aspects of these profiles. The study helped us take valuable decisions regarding profile performance without any visual assessment to decide on the best profiler engine.

scholarly journals Rotational Acceleration Measurements - Evaluating Helmet Protection

2004 ◽  
Vol 31 (4) ◽  
pp. 499-503 ◽  
Author(s):  
M. Kis ◽  
F. Saunders ◽  
M.W. ten Hove ◽  
J.R. Leslie
Keyword(s):  
Horizontal Plane ◽  
Rotational Acceleration ◽  
Testing Device ◽  
Cerebral Concussion ◽  
Impact Simulation ◽  
Head Protection ◽  
Rotational Components ◽  
Protection Devices ◽  
Testing Standards ◽  
Testing Paradigm

Purpose:Current helmet testing standards do not address the rotational components of an impact to the head. We describe a new testing paradigm used to measure the rotational acceleration of a headform and a protective helmet following an impact to the head in the horizontal plane. This impact simulation allows for the testing of currently available head protection devices in conditions thought to be important for the generation of cerebral concussion. The degree to which a particular helmet dampens rotational acceleration, and thus protects against concussion, can be assessed.Methods:Our testing device consists of a pneumatic piston that provides a measured impact to a standard headform. Four different helmets were tested using the described paradigm.Results:Acceleration curves for each helmet and the corresponding headform are presented.Conclusion:Clear differences in rotational acceleration were demonstrated. Possible avenues of further investigation are discussed.

scholarly journals The Athlete Biological Passport

2011 ◽  
Vol 57 (7) ◽  
pp. 969-976 ◽  
Author(s):  
Pierre-Edouard Sottas ◽  
Neil Robinson ◽  
Olivier Rabin ◽  
Martial Saugy
Keyword(s):  
Drug Testing ◽  
Physiological Condition ◽  
Biomarker Discovery ◽  
Physiological Changes ◽  
New Paradigm ◽  
Biological Passport ◽  
Performance Enhancing Drugs ◽  
Immense Potential ◽  
Elite Sports ◽  
Testing Paradigm

BACKGROUND In elite sports, the growing availability of doping substances identical to those naturally produced by the human body seriously limits the ability of drug-testing regimes to ensure fairness and protection of health. CONTENT The Athlete Biological Passport (ABP), the new paradigm in testing based on the personalized monitoring of biomarkers of doping, offers the enormous advantage of being independent of this endless pharmaceutical race. Doping triggers physiological changes that provide physiological enhancements. In the same way that disease-related biomarkers are invaluable tools that assist physicians in the diagnosis of pathology, specifically selected biomarkers can be used to detect doping. SUMMARY The ABP is a new testing paradigm with immense potential value in the current climate of rapid advancement in biomarker discovery. In addition to its original aim of providing proof of a doping offense, the ABP can also serve as a platform for a Rule of Sport, with the presentation before competition of the ABP to objectively demonstrate that the athlete will participate in a healthy physiological condition that is unaltered by performance-enhancing drugs. Finally, the decision-support system used today for the biological monitoring of world top-level athletes can also be advantageously transferred to other areas of clinical practice to reach the goal of personalized medicine.

To live together is to move together: marriage as testing paradigm for a social actigraphy

2019 ◽  
Vol 74 ◽  
pp. 31
Author(s):  
M. Rabuffetti ◽  
E. De Giovannini
Keyword(s):  
Testing Paradigm

Mycotoxin Testing Paradigm: Challenges and Opportunities for the Future

2019 ◽  
Vol 102 (6) ◽  
pp. 1681-1688
Author(s):  
Justin B. Renaud ◽  
J. David Miller ◽  
Mark W. Sumarah
Keyword(s):  
Agricultural Practice ◽  
Highly Qualified ◽  
Method Performance ◽  
Capital Costs ◽  
Qualified Personnel ◽  
Challenges And Opportunities ◽  
Food And Feed ◽  
Sample Testing ◽  
Feed Safety ◽  
Testing Paradigm

Mycotoxins are one of the great global challenges to agri-food and feed safety. Industry requires fast, reliable, and economical testing methods for the most important regulated mycotoxins to manage this problem. Climate change and changes in agricultural practice are complicating this situation, triggering the movement of some mycotoxins into new regions, which are unprepared for their management. Modern LC–tandem MS (LC–MS/MS) instruments have addressed this analytical challenge, but such instruments are expensive and require highly qualified personnel and dedicated facilities. As a result of these limitations, traditional LC–MS/MS is not amenable for use on farms or at small to midsized processing facilities, such as a grain elevator. To address the need for on-site rapid testing, the mycotoxin community has focused on antibody-based and spectrophotometric approaches. The development of innovative technologies such as miniaturized MS would allow for the acquisition of more information on mixtures of toxins present in a sample at costs comparable to those of the existing rapid methods such as ELISA. The capital costs are higher, but it would reduce per-sample testing costs and time requirements and provide better value for money while maintaining the accuracy and selectivity achieved in a laboratory setting. In this article, we review the available techniques and contrast them in the context of three main criteria: method performance, speed of analysis, and cost. We define the integration of these three parameters as the “mycotoxin testing paradigm.”

How much is enough to accept hormesis as the default? or ‘At what point, if ever, could/should hormesis be employed as the principal dose-response default assumption in risk assessment?'

2005 ◽  
Vol 24 (5) ◽  
pp. 245-247 ◽  
Author(s):  
Michael A Jayjock
Keyword(s):  
Molecular Biology ◽  
Dose Response ◽  
Low Doses ◽  
Human Tissues ◽  
Human Dose ◽  
Toxicological Data ◽  
Inherent Quality ◽  
Default Assumption ◽  
Testing Paradigm

Hormesis as the principal human dose-response default assumption must reasonably await the development of the science of toxicology and molecular biology before this dramatic change can occur. The inherent quality of typical toxicological data is simply too limited to allow for an understanding of what really occurs in human tissues at the relatively low doses generally extant in the environment. Thus, forwarding or asserting the quantitative use of hormesis (or any model of low doseresponse) without this reasonable knowledge is simply an argument without data. It is this writer's opinion that any widespread and default acceptance of hormesis will need to look forward to and draw upon the inevitable development and use of tools from the realm of molecular biology and a resulting and distinct change in the entire toxicological testing paradigm.

Sign in / Sign up

Export Citation Format

Share Document